Lead Product(s) : AVB-101
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AviadoBio Launches ASPIRE-FTD Phase 1/2 Trial Across Multiple UK Centers
Details : AVB-101 (AAV-PGRN) is an investigational gene therapy delivered as a one-time intrathalamic infusion, enabling distribution to brain areas affected by GRN-mutated FTD while limiting systemic exposure.
Product Name : AVB-101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 15, 2025
Lead Product(s) : AVB-101
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Linezolid
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Persica’s PP353 Phase 1b Shows Promise for Chronic Low Back Pain
Details : PP353 is an antibiotic formulation designed for intradiscal injection under image guidance. It is being evaluated for the treatment of chronic lower back pain.
Product Name : PP353
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 05, 2025
Lead Product(s) : Linezolid
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AVB-101
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Astellas Pharma
Deal Size : $2,230.0 million
Deal Type : Agreement
Astellas & AviadoBio Announce License Agreement of AVB-101 for Frontotemporal Dementia
Details : Astellas receives an exclusive option to license AVB-101, an investigational, AAV-based gene therapy in Phase 1/2 development for patients with frontotemporal dementia with progranulin mutations.
Product Name : AVB-101
Product Type : Cell and Gene therapy
Upfront Cash : $50.0 million
August 10, 2024
Lead Product(s) : AVB-101
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Astellas Pharma
Deal Size : $2,230.0 million
Deal Type : Agreement
Lead Product(s) : Linezolid
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Persica Pharmaceuticals Completes Recruitment for Chronic Pain Trial
Details : PP353 is an antibiotic formulation for intradiscal injection, under evaluation for chronic lower back pain treatment by delivering targeted antibiotic exposure.
Product Name : PP353
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 03, 2024
Lead Product(s) : Linezolid
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AVB-101
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AviadoBio Announces First Patient Treated in ASPIRE-FTD Trial Evaluating AVB-101
Details : AVB-101 is an investigational gene therapy that contains a correct (non-mutated) version of the GRN gene. It is being evaluated for the treatment of frontotemporal dementia with GRN mutations.
Product Name : AVB-101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 15, 2024
Lead Product(s) : AVB-101
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AVB-101
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : The Ohio State University Wexner Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
ASPIRE-FTD Phase 1/2 Trial Opens at Ohio State University Wexner Medical Center
Details : AVB-101 (AAV-PGRN) is an investigational gene therapy delivered as a one-time intrathalamic infusion, enabling distribution to brain areas affected by GRN-mutated FTD while limiting systemic exposure.
Product Name : AVB-101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 07, 2024
Lead Product(s) : AVB-101
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : The Ohio State University Wexner Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AVB-101
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AVB-101 is an investigational gene therapy designed to halt disease progression by delivering a functional copy of the GRN gene to restore appropriate progranulin levels in the brain for the treatment of frontotemporal dementia.
Product Name : AVB-101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 10, 2023
Lead Product(s) : AVB-101
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AVB-101
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AVB-101 is an investigational gene therapy delivered as a one-time infusion directly to the brain, enabling distribution to brain areas affected by FTD while limiting systemic exposure.
Product Name : AVB-101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 11, 2023
Lead Product(s) : AVB-101
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AXO-Lenti-PD
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Sio Gene Therapies
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Sio intends to return the global rights for AXO-Lenti-PD and that they intend to cease work on this gene therapy programme in Parkinson’s Disease. Sio is currently conducting a Phase 2 SUNRISE-PD trial with AXO-Lenti-PD.
Product Name : OXB-102
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 31, 2022
Lead Product(s) : AXO-Lenti-PD
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Sio Gene Therapies
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : AXO-Lenti-PD
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Sio Gene Therapies
Deal Size : Undisclosed
Deal Type : Agreement
Details : Oxford Biomedica will manufacture GMP batches for Axovant to support the ongoing and future clinical development of AXO-Lenti-PD, a clinical-stage gene therapy product to treat moderate to severe Parkinson’s Disease based on Oxford Biomedica’s LentiV...
Product Name : OXB-102
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 31, 2020
Lead Product(s) : AXO-Lenti-PD
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Sio Gene Therapies
Deal Size : Undisclosed
Deal Type : Agreement